Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension
Portfolio Pulse from
Mineralys Therapeutics is developing Lorundrostat, a promising candidate for treating hypertension, CKD, and OSA. The company is conducting several Phase 2 and 3 trials, with key clinical data expected this year. A potential FDA submission is anticipated by late 2026 or 2027.
January 20, 2025 | 1:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mineralys Therapeutics is advancing Lorundrostat for hypertension, CKD, and OSA, with key clinical data expected this year. Successful trials could lead to an FDA submission by 2026-2027.
The article highlights the potential of Lorundrostat, a key product for Mineralys Therapeutics, in treating hypertension and other conditions. The upcoming clinical data and potential FDA submission are significant milestones that could positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100